ProACT Therapy for the Treatment of Stress Urinary Incontinence in Males

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

123 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-08-31

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the safety and effectiveness of a minimally invasive surgical procedure in up to 109 male patients. The ProACT device is designed to treat men who have stress urinary incontinence arising from intrinsic sphincter deficiency following an operation performed on the prostate for cancer or for benign prostatic hyperplasia. Two adjustable balloons (one on each side of the urethra) are implanted to treat urinary stress incontinence.

The results will be analyzed to demonstrate the effects of the device as well as its associated risks. Therapeutic success will be based on whether patients demonstrate at least a 50% reduction in pad weight at 18 months follow-up compared to the pad weight results at baseline.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Periurethral Pro-ACTTM Balloons vs Retrourethral AdvanceXP(TM) Male Sling for Post-prostatectomy Incontinence

NCT01500603

Stress Urinary Incontinence

TERMINATED NA

Pelvic Floor Muscle Training and Biofeedback or Standard Therapy in Men Who Have Undergone Radical Prostatectomy or Transurethral Resection of the Prostate

NCT00632138

Nonmalignant Neoplasm Prostate Cancer Psychosocial Effects of Cancer and Its Treatment +2 more

COMPLETED PHASE3

Male Stress Urinary Incontinence and Sexual Health

NCT01379378

Prostate Cancer

WITHDRAWN

Effects of Urinary Bladder Hypertrophy on Urge Urine Incontinence After Radical Prostatectomy

NCT03061760

Prostate Cancer Urinary Incontinence, Urge Incontinence +2 more

UNKNOWN

Effects of Hypopressive Exercises on Urinary Incontinence and Erectile Dysfunction After Radical Prostatectomy

NCT07101731

Prostate Cancer (Post Prostatectomy) Urinary Incontinence Erectile Dysfunction Following Radical Prostatectomy +1 more

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is a prospective, non-randomized multi-center investigation. Multiple measurements using 24 hour pad weight and pad count, validated questionnaires, voiding diaries will be used to evaluate the achievement of the study objectives. Subjects will be followed for a minimum of 18 months following implantation. Subjects will be requested to continue annual follow-ups through the FDA approval.

The purpose of the study is to evaluate the safety and effectiveness of a minimally invasive surgical procedure in up to 109 male patients. The ProACT device is designed to treat men who have stress urinary incontinence arising from intrinsic sphincter deficiency following an operation performed on the prostate for cancer or for benign prostatic hyperplasia. Two adjustable balloons (one on each side of the urethra) are implanted to treat urinary stress incontinence.

The results will be analyzed to demonstrate the effects of the device as well as its associated risks. Therapeutic success will be based on whether patients demonstrate at least a 50% reduction in pad weight at 18 months follow-up compared to the pad weight results at baseline.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urinary Incontinence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ProACT (Adjustable Continence Therapy)

Implantation with ProACT (Adjustable Continence Therapy), Single Arm

Group Type EXPERIMENTAL

ProACT (Adjustable Continence Therapy)

Intervention Type DEVICE

Implantable device to reduce urinary stress incontinence

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ProACT (Adjustable Continence Therapy)

Implantable device to reduce urinary stress incontinence

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ProACT,Adjustable Incontinence therapy for Males

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Undergone either a radical prostatectomy, transurethral resection of the prostate or other prostate surgery at least 12 months prior without radiation therapy
* Demonstrate primary stress urinary incontinence
* Male subjects at least 45 years of age
* Willing and able to undergo surgical implantation of the ProACT devices
* Willing and able to comply with the follow-up requirements
* Willing and able to forego any other surgical urinary incontinence treatments while participating in the study
* Willing and able to sign the informed consent
* Positive 24 hour pad weight tests (greater than or equal to 8 gram pad weight increase demonstrated in two 24-hour pad weight tests)
* Experiences at least 3 incontinence episodes per day during two baseline voiding diaries.
* Negative Urine culture
* No recurrent stricture at the anastamosis
* No known urogenital malignancy other than previously treated prostate cancer
* Physician determines subject to be suitable surgical candidate

Exclusion Criteria

* Primarily Urge incontinence
* Detrusor instability or over-activity
* Residual volume greater that 100 ml or greater than 25% of the total bladder capacity after voiding.
* Subject has/had or is suspected of having bladder cancer
* History of recurrent bladder stones
* Neurogenic bladder that is atonic or has detrusor sphincter dyssynergia
* Known hemophilia or a bleeding disorder
* Abnormal PSA (Prostate Specific Antigen), according to sites laboratory standards, unless further investigation confirms no underlying prostate malignancy.
* Known sever contrast solution allergy
* Has a genitourinary mechanical prosthesis other than previous sling procedure (e.g., Artificial Urinary sphincter, implantable penile prosthesis)
* Has a urethral stricture that prevents passage of an 18 F cystoscope or has had more than one urethrotomy
* Undergone bulking procedure within 6 months of the baseline assessment
* Subject is currently enrolled or plans to enroll in another device or drug clinical trial.
* Subject is currently using an indwelling catheter or condom catheter for treatment of incontinence and is not willing to discontinue use at least 4 weeks prior to baseline assessment.

Minimum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes